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Summary
Objective: To assess the effect of the immunosuppressant FK506 on chondrogenic differentiation of human synovial stromal cells (hSSCs).
Methods: hSSCs were isolated from synovium of the knee joint and 2 105 cells were subjected to pellet culture in chondrogenic culture me-
dium for 3 weeks with or without growth factors [bone morphogenetic protein 2 (BMP2) or transforming growth factor b1 (TGFb1)] and þ/
addition of FK506 in chondrogenic culture media was evaluated. Chondrogenesis was assessed by the size of the pellet, the production
of proteoglycans, and messenger RNA (mRNA) levels for chondrogenic markers. Furthermore, levels and intracellular location of phosphor-
ylated Smad proteins related to BMP signaling and TGFb signaling were evaluated following exposure to FK506.
Results: FK506 enhanced the differentiation of hSSCs toward a chondrogenic phenotype in a dose-dependent manner associated with in-
creases in glycosaminoglycan synthesis and increased mRNA levels for chondrogenic marker genes. Additionally, FK506 further enhanced
chondrogenesis of synovial stromal cells (SSCs) induced by BMP2 and TGFb1, also in a dose-dependent manner. Notably, phosphorylation of
Smad1/5/8 and Smad3 was signiﬁcantly increased by FK506. Also, the ratio of nuclear translocation to cytoplasmic levels of phosphorylated
Smad1/5/8 and Smad3 were increased following exposure of SSCs to FK506. Moreover, inhibition of Smad signaling signiﬁcantly abrogated
FK506-induced chondrogenic differentiation of SSCs.
Conclusion: This study demonstrated that FK506 promotes chondrogenic differentiation of hSSCs likely via impact on Smad signaling path-
ways. With further optimization, FK506 could potentially be a unique therapeutic tool to promote cartilage repair in clinical situations, as well as
enhance development of tissue engineered cartilage in vitro.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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It is well known that the healing potential of articular carti-
lage is limited, in part, due to its avascularity1. To compen-
sate for such poor healing capacity, several cell-based
approaches have been investigated to repair chondral le-
sions. Among them, autologous chondrocyte implantation
(ACI) procedures have been widely performed2. Despite
their promising clinical results3,4, the limitations of this pro-
cedure may be related to the cell source and the in vitro ex-
pansion of the cells. Chondrocytes are often obtained from
uninvolved cartilage tissue at minor load-bearing areas of
the same joint. However, potential problems related to do-
nor-site morbidity, which may increase the risk of develop-
ing osteoarthritis later in life remain unclear. In addition, it
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Received 4 October 2006; revision accepted 2 January 2007.70may be difﬁcult to obtain a sufﬁcient amount of healthy car-
tilage from joints in elderly patients due to the age-related
development and progression of osteoarthritis. Chondro-
cyte expansion is likely another crucial factor for successful
treatment. However, chondrocyte expansion in monolayer
cultures usually results in dedifferentiation cells with in-
creasing passage5e7 and such loss of chondrogenic capac-
ity may account for variable clinical results of ACI3,8,9.
Mesenchymal stem cells (MSCs) were ﬁrst identiﬁed in
bone marrow and shown to have the ability to differentiate
into a variety of connective tissue phenotypes including
bone, cartilage, and adipose-tissue10,11. Recent studies
have revealed that MSCs are also present in various tis-
sues such as umbilical cord blood12, muscle13, adipose-tis-
sue14,15, tendon16, and synovium17,18. Speciﬁcally, MSCs
derived from synovium have been shown to have the ability
to proliferate over many passages without losing their multi-
potency, and such expansion appears to be independent of
donor age or cryopreservation17. In addition, a recent study
has shown that MSCs derived from synovium are superior
to those from bone marrow or adipose tissue in terms of
chondrogenic differentiation19 and it is a relatively easy
and safe procedure to obtain cells from synovium with9
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rived MSCs could be a promising source for future cell-
based cartilage repair.
FK506 (tacrolimus) is a widely used immunosuppressive
agent with Food and Drug Administration (FDA) approval,
usually used to prevent graft rejection. The immunosuppres-
sive effect of FK506 is believed to be related to its ability to in-
hibit calcineurin, an enzyme involved in the activation of the
nuclear factor of activated T cells (NFAT)20. Recent studies
also suggest the involvement of NFAT in chondrogene-
sis21,22. Furthermore, it has been shown that FK506 can
induce chondrogenic differentiation of clonal mouse embry-
onic carcinoma cells (ATDC5), although the molecular target
for its effect on chondrogenesis remains unclear23. Such
observations raise the possibility that FK506 might likewise
promote chondrogenic differentiation of MSCs. To test this
hypothesis, the effect of FK506 on chondrogenic differen-
tiation of human synovial stromal cells (hSSCs) was investi-
gated. Furthermore, the molecular mechanism(s) underlying
the promotion of chondrogenic differentiation by FK506 were
explored.
Materials and methods
ISOLATION AND EXPANSION OF SYNOVIAL STROMAL CELLS
(SSCs)
SSCs were isolated from human synovium which was har-
vested from the knee joint of four patients during arthroscopic
surgery in accordancewith a protocol approved by theOsaka
University Institutional Ethics Committee. The demographics
of the patients who provided samples are summarized in
Table I. Inﬂamed knees were excluded in this study.
Synoviumwas digested with 0.4% collagenase (Worthington
Bio. Chem., New Jersey, USA) for 2 h, and then the resultant
cells were washed twice with phosphate buffered saline
(PBS) and subsequently cultured in high glucose Dulbecco’s
modiﬁedEagle’smedium (HG-DMEM;GibcoBRL, Life Tech-
nologies Inc, Maryland, USA) containing 10% fetal bovine
serum (FBS; HyClone, Utah, USA) and 1% Penicillin/
Streptomycin (Gibco BRL, Life Technologies Inc) in humidi-
ﬁed air with 5%CO2at 37
C. To expand the cultures, the cells
were harvested, diluted at 1:3, and replated.
IN VITRO CHONDROGENESIS
To assess chondrogenic differentiation, a pellet culture sys-
tem was used24. Approximately 2 105 cells (passages 3e5)
were placed in a 15-ml polypropylene tube, and centrifuged
at 500g for 10 min. The pellets were cultured at 37C with 5%
CO2 in 500 ml of chondrogenic culture medium that contained
HG-DMEMwith 10% FBS, supplemented with 50 mg/ml ascor-
bate-2-phosphate, 100 mg/ml sodium pyruvate, and 50 mg/ml
insulin, transferrin, and selenious acid (ITS)þ Premix (BD
Table I
Summary of patients
Age Sex Sample volume (mg) Diagnosis
Patient 1 19 M 230 Lt ACL injury
Patient 2 57 F 750 Lt OCD
Patient 3 23 F 450 Lt ACL injury
Patient 4 26 M 552 Rt ACL injury
The characteristics of patients involved in this study are indicated
in the table. None of the patients was arthritic at the time of surgery.
Patients underwent arthroscopic surgery for anterior cruciate liga-
ment (ACL) injury or osteochondritis dissecans (OCD).Biosciences, California, USA), as described previously25. To
assess the inﬂuence of FK506, the cell pellets were cultured
in a chondrogenic culture medium supplemented with 0.1 or
1 mg/ml of FK506. Moreover, to evaluate the effect of FK506
with those of growth factors, 10 ng/ml transforming growth fac-
tor b1 (TGFb1) (R&D Systems, Abingdon, UK) or 100 ng/ml re-
combinant human bone morphogenetic protein 2 (rhBMP2) (a
generous gift from Wyeth, Massachusetts, USA) was added
to the medium. The optimal concentration of bone morpho-
genetic protein 2 (BMP2) or TGFb1 was determined from
preliminary in vitro optimization studies on chondrogenic differ-
entiation of hSSCs in pellet cultures (unpublished data). The
medium was replaced twice per week for 3 weeks.
CELL PELLET SIZE ANALYSIS
After 3weeks of culture, the cell pelletswere harvested and
macroscopic analysis was performed by stereomicroscopic
procedures. The images were analyzed by WinROOF (Mi-
tani, Osaka, Japan), and then the cross-sectional area
(CSA) of pellets was calculated in two-dimensional (2-D)
image and the CSA was evaluated as a parameter of pellet
size.
HISTOLOGICAL ASSESSMENT
The cell pellet cultures were ﬁxed in 4% paraformalde-
hyde, rinsed twice with PBS, embedded in parafﬁn, cut
into 5 mm sections, and then stained for 2 h at room temper-
ature with 1% Alcian blue (Alcian Blue 8 GX; Sigma, Mis-
souri, USA) in 0.1 N HCl, and subsequently counter
stained with kernechtrot.
MEASUREMENT OF GLYCOSAMINOGLYCAN (GAG) LEVELS
Proteoglycan levels in the pellets were measured by
a color method as described previously26, with minor mod-
iﬁcation. Brieﬂy, synovial cell pellets were digested for 4 h at
65 C with a papain solution (Sigma). Samples from the pa-
pain digest were subsequently assayed for GAG as a mea-
sure of proteoglycan content. GAGs were assayed using
the 1,9-dimethylmethylene blue binding (DMMB) assay, us-
ing a chondroitin sulfate standard curve (Nacalai Tesque,
Kyoto, Japan).
REAL-TIME REVERSE TRANSCRIPTASE POLYMERASE CHAIN
REACTION (RT-PCR)
Total RNA was extracted from synovial cell pellets using
the TRIzol Reagent (Invitrogen Life Technologies, California,
USA), and 1 mg of total RNA was reverse transcribed into
cDNA with Super Script III (Invitrogen Life Technologies) fol-
lowing the manufacturer’s instructions. Real-time polymer-
ase chain reaction (PCR) conditions were optimized for
maximal PCR efﬁciency by adjustment of concentrations of
the following PCR primers: Sox9, CAC ACA GCT CAC
TCG ACC TT (forward) and CAA AGG GAA TTC TGG TTG
GT (reverse); Collagen IIa1, TCT ACC CCA ATC CAG
CAA AC (forward) and GTT GGG AGC CAG ATT GTC AT
(reverse); Aggrecan, TGA GTC CTC AAG CCT CCT GT
(forward) and TGG TCT GCA GCA GTT GAT TC (reverse);
Collagen X, GGT TTT CCG GGA GAA ATG GGA CCA A
(forward) and CTG GAG CCC CAG GGA GAC CTT TTG T
(reverse); glyseraldehyde-3-phosphate dehydrogenase
(GAPDH), AGC CAA AAG GGT CAT CAT CTC (forward)
and GTT GTC ATG GAT GAC CTT GG (reverse). Real-
timePCRwas performed using a LightCycler System (Roche
Applied Science, Mannheim, Germany).
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Cell cultures in six-well culture dishes at 3 104/cm2,
maintained for the indicated time periods, were washed
twice with ice-cold PBS, lysed with sample buffer
(62.5 mM TriseHCl, pH 6.8 at 25C, 2% sodium dodecyl
sulfate (SDS), 10% glycerol, 50 mM dithiothreitol (DTT),
and 0.01% bromophenol blue), incubated on ice for
10 min, homogenized by sonication, and centrifuged at
12,000g for 5 min. Equal amounts of the supernatant were
then fractionated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE); electroblotted onto Hy-
bond-P membrane (Amersham Pharmacia Biotech, New
Jersey, USA) and then probed with antibodies to Smad1/5
(Calbiochem, Darmstadt, Germany), phospho-Smad1/5/8
(Cell Signaling Technology, Massachusetts, USA), Smad2/3
(Cell Signaling Technology), phospho-Smad3 (Cell Signal-
ing Technology) and proliferation cell nuclear antigen
(PCNA) (Santa Cruz Biotechnology, California, USA). The
blots were developed using the ECL Western blotting detec-
tion kit according to the manufacturer’s protocol (Amersham
Pharmacia Biotech) and visualized by the Lumino Imaging
Analyzer FAS-1000 (Toyobo, Osaka, Japan). The detected
signals were then subjected to densitometric analyses by
ImageJ (NIH, Maryland, USA)27, and quantiﬁed results
are presented as integrated optimal density (IOD)28.
SUBCELLULAR FRACTIONATION
SSCs were cultured in six-well culture dishes at 3 104/
cm2. After a 30-min treatment with 1 mg/ml FK506, SSCs
were washed twice with ice-cold PBS, and were then
scraped from the wells, and lysed in 100 ml of buffer A
(10 mM KCl, 10 mM hydroxyethyl-1-piperadinyl ethansul-
fonic acid-potassium hydroxide (HEPES-KOH), pH 7.6,
1.5 mM MgCl2, 1 mM DTT, 0.5 mM phenylmethylsulfonyl
ﬂuoride) for 10 min on ice. Supernatants were retained as
the cytoplasmic fractions. Precipitated nuclei were lysed in
50 ml of buffer B (420 mM NaCl, 10 mM HEPES-KOH, pH
7.6, 1.5 mM MgCl2, 1 mM DTT, and 0.5 mM phenylmethyl-
sulfonyl ﬂuoride) for 15 min on ice29.
INHIBITION OF SMAD SIGNALING PATHWAYS
To investigate the relationship of Smad signaling pathways
to FK506-mediated chondrogenesis, a commercially avail-
able speciﬁc pathway inhibitor and an antagonist were used;
500 ng/ml recombinant human Noggin (RELIATech,
Braunschweig, Germany) is an antagonist of BMPs, including
BMP230, and 1 mM SB431542 (Sigma) is a selective inhibitor
of the TGFb type I receptor31. The optimal dose of these inhib-
itors was adopted based on previous in vitro studies32,33.
STATISTICAL ANALYSIS
All experiments were performed in triplicate. Statistical
signiﬁcance of the data was evaluated by analysis of vari-
ance (ANOVA) with the Bonferroni correction. The null hy-
pothesis was rejected at P< 0.05.
Results
FK506 PROMOTES CHONDROGENIC DIFFERENTIATION OF
SSCs
It has been reported that the degree of chondrogenic dif-
ferentiation is related to pellet size and weight24, based onincreases in proteoglycan synthesis34. SSC pellets cultured
in chondrogenic culture medium with FK506 were signiﬁ-
cantly larger than those cultured without FK506 [Fig. 1(a)].
Increases in pellet size were observed in a dose-dependent
manner, but were most prominent at 1000 ng/ml FK506
(mean of 27.5%) [Fig. 1(b)]. Exposure to FK506 also en-
hanced Alcian blue staining of the cell pellets. Increases
in staining were prominent in the center area of the
FK506-treated cell pellets, and the staining intensity ex-
hibited a dose dependency [Fig. 1(c)]. Likewise, exposure
to FK506 signiﬁcantly increased GAG levels in the pellets
[Fig. 1(d)] and again these exhibited a dose dependency
with increases of approximately eight-fold when FK506
was added at 1000 ng/ml.
FK506 AND BMP2/TGFb1 ADDITIVELY PROMOTE CHONDRO-
GENESIS IN hSSCs
To investigate whether the effects of FK506 on chondro-
genesis were additive or synergistic with those observed for
chondrogenic growth factors, the pellet culture system in
the presence of growth factors (BMP2 or TGFb1) and sev-
eral doses of FK506 was assessed. In combination with
BMP2 or TGFb1, FK506 additively increased both the size
of the cell pellet [Fig. 2(a) and (b)] and GAG levels
[Fig. 2(c) and (d)] in a dose-dependent manner. RT-PCR
analysis showed that FK506-treated cell pellets exhibited
increased messenger RNA (mRNA) levels for collagen
IIa1 and aggrecan irrespective of the presence of growth
factors, and the positive effects of FK506 on chondrogene-
sis were signiﬁcantly promoted in combination with BMP2 or
TGFb1 [Fig. 2(e)]. Type X collagen gene expression was not
detected after 3 weeks of culture in any of the control or ex-
perimental conditions (data not shown). However, after 6
weeks of culture, expression of the type X collagen gene
in the BMP2/TGFb1 supplemented groups was detected
(data not shown).
INVOLVEMENT OF SMAD SIGNALING PATHWAYS IN FK506-
INDUCED SSCs’ DIFFERENTIATION
Since FK506 appeared to exhibit an additive effect with
not only BMP2 but also TGFb1, both of which are members
of the TGFb superfamily, the potential involvement of Smad
signaling pathway in FK506-mediated chondrogenesis was
further investigated. The phosphorylation of Smad1/5/8 and
Smad3 was readily detected following chondrogenic me-
dium treatment of SSCs. In FK506-treated cells, phospho-
Smad1/5/8 and phospho-Smad3 levels were signiﬁcantly
higher than those in nontreated cells by 20e40% (P< 0.01)
after 30 min, 60 min, and 120 min of exposure to the drug
[Fig. 3(a)e(d)]. In addition, levels of phospho-Smad1/5/8
and phospho-Smad3 were signiﬁcantly elevated in both
the nuclear and cytoplasmic fractions after FK506 treatment
[Fig. 3(e)]. These data suggest that FK506 treatment has
signiﬁcant effects on the phosphorylation state of Smad
proteins.
INHIBITION OF SMAD SIGNALING PATHWAYS INHIBIT FK506-
INDUCED CHONDROGENESIS OF hSSCs
To further clarify the relationship of FK506-mediated
chondrogenesis and Smad signaling, pellet cultures were
performed with inhibitors of Smad activation; BMP antago-
nist, Noggin, and a TGFb receptor type I (TGFbRI) blocker,
SB431542. The size of pellet cultures and the GAG levels in
pellet cultures were signiﬁcantly decreased with both
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Fig. 1. Inﬂuence of FK506 on chondrogenic differentiation of hSSCs in vitro. Exposure to FK506 leads to signiﬁcantly enlarged pellet culture
size of SSCs (a). The sizes of pellets were quantiﬁed as CSA from 2-D images of pellets (b). FK506 enhancement of Alcian blue staining in the
pellet cultures (c). Increases in the staining are prominent in the center area of FK506-treated pellet cultures and the staining intensity in-
creased in a dose-dependent manner. Likewise, according to DMMB assays, FK506 exposure signiﬁcantly increased GAG levels in the pellet
cultures in a dose-dependent manner (d). (a) Bar¼ 1 mm. (c) Bar¼ 100 mm. Each error bar represents the standard error of the mean.inhibitors [Fig. 4(a) and (b)]. Moreover, the FK506-mediated
elevation of phospho-Smad1/5/8 was reduced after Noggin
treatment, and that of phospho-Smad3 was reduced after
SB431542 treatment [Fig. 4(c) and (d)].
Discussion
The present studies demonstrate that a widely used im-
munosuppressant, FK506, promotes chondrogenic differ-
entiation of hSSCs and moreover, that FK506 additively
enhances chondrogenic differentiation of hSSCs in the
presence of chondrogenic growth factors, such as BMP2
and TGFb1. In all experiment, type X collagen expression
was not detected at 3 weeks after FK506 treatment, but
was detected after 6 weeks of treatment. However, the ex-
pression level of type X collagen was not affected by the
treatment (data not shown). These results indicated that
FK506 treatment effectively promoted early chondrogenic
differentiation of hSSCs. In addition, results were pre-
sented which indicate that the Smad signaling pathways
are involved in the FK506 effects on SSC differentiation to-
ward a chondrogenic phenotype.
The results clearly show that FK506 enhanced phos-
phorylation of Smad1/5/8 and Smad3. Moreover, nuclear
translocation of Smad1/5/8 and Smad3 was also promoted
after exposure of SSC to FK506. These data suggest that
chondrogenic regulatory transcription factors might be acti-
vated by Smad pathways after FK506 treatment. Further-
more, inhibition of BMP/TGFb-receptor-mediated Smadactivation partially abrogated FK506-induced chondrogene-
sis of hSSCs. Therefore, the molecular mechanisms related
to FK506-mediated enhancement of SSC differentiation to
the chondrogenic phenotype may be related in part to activa-
tion ofSmadpathways.However, the speciﬁc site of this inﬂu-
ence on Smad pathway activation remains to be elucidated.
It should be noted that FK506 effects on chondrogenic
differentiation were complementary to those of both BMP2
and TGFb1 for enhancement of chondrogenic phenotypic
differentiation by SSC. As the TGFb superfamily is also
known to regulate the phosphorylation of speciﬁc recep-
tor-regulatory Smad35, there was reason to believe that
FK506 action and BMP2/TGFb1 actions may be comple-
mentary. While BMP2 signaling is mediated by Smad1,
Smad5, and Smad8, TGFb1 signaling is reported to be via
Smad2 and Smad335. It is well known that the Smad1/5/8
signaling pathway is involved in BMP-mediated chondro-
genesis36, while it has also been recently reported that
the Smad3 pathway plays a key role in Sox9-dependent
transcriptional activation in primary chondrogenesis29.
Therefore, the current ﬁndings that FK506 and BMP2/
TGFb1 exerted additive effects on SSC differentiation to-
ward the chondrogenic phenotype are consistent with this
knowledge base.
FK506 is believed to exert its immunosuppressive effects
after binding to intracellular proteins, termed FK506 binding
proteins (FKBPs) and known as immunophilins. Members of
the TGFb superfamily are known to bind to transmembrane
receptors that consist of heteromeric serine/threonine
713Osteoarthritis and Cartilage Vol. 15, No. 6BMP2
100ng/ml
1mm
TGFβ
1
10ng/ml
1mm
Dose of FK506 (ng/ml)
10001000
(a)
Dose of FK506 (ng/ml) 
0
1
2
3
4
5
6
7
8
10001000
C
S
A
 
(
m
m
2
)
BMP2+TGFβ1+
(b)
0
0.5
1
1.5
2
2.5
3
3.5
10001000
C
S
A
 
(
m
m
2
)
Dose of FK506 (ng/ml) 
∗
∗
∗
∗
p<0.05
∗
BMP2
100ng/ml
TGFβ
1
10ng/ml
Dose of FK506 (ng/ml)
10001000
(c)
100μm
Fig. 2. FK506 enhances chondrogenic differentiation of SSCs and such enhancement is complementary to that induced by BMP2 and TGFb1.
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the upper left panel, the macroscopic appearance of a nontreated pellet culture is demonstrated within the square frame. The sizes of pellets
were quantiﬁed as CSA (b), and GAG level of pellet cultures determined using the DMMB assay (d). The sizes and GAG levels of pellets were
increased with FK506 treatment in a dose-dependent manner. RT-PCR showed that FK506-treated pellet cultures exhibited increased expres-
sion of collagen IIa1 and aggrecan irrespective of the presence of growth factors, and a signiﬁcantly positive effect of FK506 was observed in
combination with BMP2 or TGFb1 (e). (a) Bar¼ 1 mm. (c) Bar¼ 100 mm. (e) Oblique line bar, TGFb treatment group; open bar, BMP2 treat-
ment group. Each error bar represents the standard error of the mean values.
714 K. Tateishi et al.: FK 506 promotes development of the chondrogenic phenotype in hSSCs(d)
Dose of FK506 (ng/ml)
0
5
10
15
20
25
1000
TGFβ1
TGFβ1
1000
Dose of FK506 (ng/ml)
50
60
70
80
10001000
40
30
20
10
0
∗
∗
p<0.05 ∗
∗
∗
∗
∗
(e)
0
0.01
0.02
0.03
0.04
0.05
0.06
10001000
Aggrecan
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
10001000
A
g
g
r
e
c
a
n
/
G
A
P
D
H
BMP2+
BMP2
Dose of FK506 (ng/ml)
Dose of FK506 (ng/ml) Dose of FK506 (ng/ml)
Dose of FK506 (ng/ml)
0
0.005
0.01
0.015
0.02
0.025
0.03
0.035
10001000
Aggrecan
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
10001000
A
g
g
r
e
c
a
n
/
G
A
P
D
H
∗
∗
∗
∗
∗
∗
p<0.05
∗
n.s
n.s
G
A
G
 
l
e
v
e
l
s
 
(
 
 
g
/
 
 
g
 
p
r
o
t
e
i
n
)
G
A
G
 
l
e
v
e
l
s
 
(
 
 
g
/
 
 
g
 
p
r
o
t
e
i
n
)
C
o
l
l
a
g
e
n
 
I
I
 
 
1
/
G
A
P
D
H
Collagen2  1
Collagen2  1
C
o
l
l
a
g
e
n
 
I
I
 
 
1
/
G
A
P
D
H
Fig. 2. (Continued)kinase subunits (type I and type II)37. The immunophilin
FKBP12 is one of the targets for FK506 which binds to the
GS region of the type I receptor, capping the type II receptor
phosphorylation sites and further stabilizing the inactive con-
formation of the type I receptor38,39. FK506 treatment may
therefore cause binding to FKBP12 and resultant decline
in receptor stability. Thus, the binding of FK506 to FKBP12
could lead to further activation of TGFb signaling. However,a recent study reported that overexpression of FKBP12 sup-
pressed Smad1/5/8 signaling induced by FK506, and that
BMPRIA and FKBP12 bound to each other when they
were overexpressed in 293 cells40. Thus, it has been sug-
gested that FKBP12 may also bind to the BMP receptor
and likewise inactivate BMP signaling. Taken together,
FK506 may activate both BMP signaling and TGFb signaling
by interfering with the ability of blocking FKBPs to bind to
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Fig. 3. Inﬂuence of FK506 on phosphorylation of components of the Smad signaling pathways. The time course for induction of phospho-
Smads in SSCs after FK506 stimulation as assessed by Western blotting. In FK506-treated cells, phospho-Smad1/5/8 and phospho-
Smad3 levels were signiﬁcantly higher than those in nontreated cells after 30 min, 60 min, and 120 min (a,c). Signiﬁcant differences between
FK506-treated cells and nontreated cells were detected from the quantiﬁcation of IOD measurements of phospho-Smad1/5/8 (3) to total-
Smad1/5 (2/3) (b,d). The expression of phospho-Smad1/5/8 and phospho-Smad3 were signiﬁcantly elevated in both the nuclear and cytoplas-
mic fractions after FK506 treatment (e). Each error bar represents the standard error of the mean.their type I receptors. Further investigation will be needed to
clarify such possibilities.
It has been suggested that several signaling pathways
may be involved in chondrogenic differentiation of
MSCs41e43. A potential linkage of FK506-mediated chon-
drogenesis to other signaling pathways, such as the p38
mitogen-activated protein kinase (MAPK), MAPK kinase
(MEK), and PI3K pathways were investigated using speciﬁc
inhibitors of these signaling pathways. However, none of
the inhibitors affected the chondrogenic effects of FK506
(data not shown). Therefore, further investigation will beneeded to clarify the molecular mechanisms responsible
for FK506-mediated enhancement of SSC differentiation
to the chondrogenic phenotype.
Finally, although FK506 is already used in patients clin-
ically for therapeutic purposes, particularly to prevent graft
rejection; the concentrations of FK506 used in this in vitro
study were in a somewhat higher range than those re-
quired for other applications44. Furthermore, it has been
reported that chronic administration of FK506 might have
potential risk of oncogenesis45, and therefore, careful anal-
ysis will be required to test the effect of FK506 in
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Fig. 4. Inhibition of Smad pathways partially abrogates FK506-induced chondrogenesis of hSSCs. In the presence of Noggin, a BMP antag-
onist, or SB431542, a TGFb receptor I inhibitor, the FK506-mediated increases in size of pellet cultures were signiﬁcantly decreased (a) and
GAG levels also decreased with signiﬁcant differences detected (b). FK506-mediated enhancement of chondrogenesis of hSSCs was partially
suppressed by inhibition of Smad signaling pathways. The elevations in phospho-Smad1/5/8 levels after FK506 treatment were down-regu-
lated by Noggin and those for phospho-Smad3 were down-regulated by SB431542 (c). Semiquantiﬁcation revealed down-regulation by both
inhibitors was signiﬁcant (P< 0.05) (d). Solid bar, FK506 treatment group; open bar, FK506 nontreatment group. Each error bar represents the
standard error of the mean.experimental model systems to further explore its potential
to enhance chondrogenesis. However, this unique com-
pound might be suitable for local administration in the
area of cartilage repair or for applications in an ex vivo
strategy to enhance the tissue engineering of cartilage.
Signiﬁcantly, FK506 could very practically contribute to re-
ductions in the doses of chondrogenic growth factors such
as BMP2 and TGFb1 required to induce a comparable
chondrogenic differentiation response. Furthermore, inthe present study, FK506 did not affect the hypertrophy
of chondrocytes. This beneﬁt may also decrease the risk
of adverse effects of growth factors and also could poten-
tially contribute to a reduction in medical costs for such
procedures.
With further optimization, FK506 could potentially be-
come a unique therapeutic reagent to promote cartilage
repair, alone or in combination with other modalities, either
in vivo or in vitro.
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